Foghorn Therapeutics Inc. has released its financial results for the first quarter of 2025. The company reported collaboration revenue of $6.0 million for the three months ended March 31, 2025, an increase from $5.1 million in the same period of 2024. This growth was driven by the advancement of programs under the Lilly Collaboration Agreement. The company's net loss for the quarter was $18.8 million, showing a reduction from the net loss of $25.0 million reported for the same period the previous year. Research and development expenses decreased to $21.6 million for the quarter, compared to $25.5 million in the first quarter of 2024. The decrease was primarily due to reduced costs associated with FHD-286 and other personnel-related expenses, although there was an increase in costs related to Lilly-partnered programs. General and administrative expenses also saw a reduction, totaling $7.2 million compared to $7.7 million the previous year, primarily due to lower consulting costs. Foghorn Therapeutics reported cash, cash equivalents, and marketable securities amounting to $220.6 million as of March 31, 2025, which is expected to provide a cash runway into 2027. Operationally, the company is advancing its FHD-909 Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer as the primary target. Additionally, the company is progressing with its selective CBP degrader, targeting IND-enabling studies and an IND filing in 2026, while updates on the selective EP300 degrader and selective ARID1B degrader programs are expected in the second half of 2025.